MARLBOROUGH, Mass., Oct. 24, 2016 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced key data which will be presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in Washington, D.C., on October 29 – November 2.
Notably, WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device data will be featured in a late-breaking clinical trial session on Wednesday, November 2, and will highlight the procedural safety of the device since it became commercially available in the U.S. in March 2015. Additionally, the PLATINUM Diversity trial which examined acute procedural performance with the Promus PREMIER™ Everolimus-Eluting Stent in women and minorities – historically underrepresented patient populations in clinical trials – will be presented at the first report investigation session on Tuesday, November 1.
Other oral presentations of interest include PREVAIL three-year and PROTECT AF five-year follow-up data related to long-term event rates for LAA closure with the WATCHMAN device and three-year outcomes of the Lotus™ Valve System in high-risk patients with severe aortic stenosis.
"Over the course of my thirty-year career as an interventional cardiologist and chief medical officer, there has been a renaissance in the treatment of heart disease – with a surging reliance on minimally-invasive devices to deliver the outcomes previously achieved with surgery," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "In addition to enhancing the established body of clinical evidence for our products which treat coronary and peripheral artery disease, this meeting will demonstrate the exceptional advancement of our Structural Heart portfolio – comprised of the Lotus Valve System for transcatheter aortic valve replacement, and the WATCHMAN device, the only FDA-approved LAAC device."
ORAL ABSTRACTS OF INTEREST (listed chronologically)
Monday, October 31
Oral Abstract Sessions
- WATCHMAN LAAC Device: Long-Term Event Rates for Left Atrial Appendage Closure with WATCHMAN: PROTECT AF Five-Year and PREVAIL Three-Year Follow-up: Vivek Reddy, M.D., will present at 12:15 PM in Room 203, Level 2.
- Lotus Valve System: Three-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II CE-Mark Study: Professor Ian Meredith will present at 12:30 PM in Room 203, Level 2.
Tuesday, November 1
First Report Investigation
- PLATINUM DIVERSITY: Outcomes from a Large-Scale, Prospective Registry of Coronary Artery Stent Implantation in Women and Minorities: Wayne B. Batchelor, M.D., will present at 12:45 PM in the Ballroom, Level 3.
Wednesday, November 2
Late-Breaking Clinical Trial
- WATCHMAN LAAC Device: Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation: David Holmes Jr, M.D., will present at 9:20 AM in the Ballroom, Level 3.
POSTER ABSTRACTS OF INTEREST
The following poster abstracts will be available for viewing on Saturday, October 29, from 6:00 PM – 8:00 PM in Hall B, Lower Level:
- Eluvia™ Drug-Eluting Vascular Stent System: Vascular Healing Response after Implantation of a Novel Fluoropolymer-Coated Paclitaxel-Eluting Peripheral Stent: a Comparative Drug-Eluting Stent Study in a Familial Hypercholesterolemic Swine Model of Balloon-Injured Femoral Arteries: A poster by Dr. Juan Granada, M.D.
- Lotus Valve System: Four-Year Clinical Outcomes Following TAVR with the Repositionable and Fully Retrievable Lotus Valve System: an Update from the REPRISE I Study: A poster by Professor Ian Meredith, M.D.
- Lotus Valve System: Predictors of Permanent Pacemaker Implantation in Patients Treated in Routine Clinical Practice with the Repositionable and Fully Retrievable Lotus Valve: A poster by Dr. Nicolas Van Mieghem, M.D., Ph.D.
- WATCHMAN LAAC Device: Cost Effectiveness Following Treatment Initiation of Stroke Reduction Strategies in Non-Valvular Atrial Fibrillation: Warfarin vs NOACs vs Left Atrial Appendage Closure: A poster by Dr. Vivek Reddy, M.D.
- WATCHMAN LAAC Device: Do patients with CKD benefit from Left Atrial Appendage Closure (LAAC) with WATCHMAN? Insights from PROTECT AF: A poster by Dr. Miguel Valderrabano, M.D.
- WATCHMAN LAAC Device: Safety and Efficacy of Left Atrial Appendage Closure with the Watchman Device in Patients Older than 85 Years Old. Data from the Prospective EWOLUTION Registry: A poster by Dr. Ignacio Cruz Gonzalez, M.D.
All presentations are listed in Eastern Daylight Time and will take place at the Walter E. Washington Convention Center. For more information, visit Boston Scientific at booth #1525.
The company will also host an investor event and webcast at their booth on Monday, October 31, from 9:15 – 10:00 AM EDT to provide a presentation and answer questions from investors about the Boston Scientific cardiovascular portfolio. The event will be accessible at www.bostonscientific.com/investors. A replay of the webcast will be accessible at www.bostonscientific.com/investors beginning approximately one hour following the completion of the event.
In the U.S., the Lotus Valve System and the Eluvia Stent System are investigational devices and are not available for sale.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Boston Scientific Corporation
(651) 582-5887 (office)
Susie Lisa, CFA
Boston Scientific Corporation
(508) 683-5565 (office)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-scheduled-presentations-at-transcatheter-cardiovascular-therapeutics-2016-300349874.html
SOURCE Boston Scientific